Clinical Trials

INDIANAPOLIS — U.S. Surgeon General Jerome Adams said medical marijuana should be studied and treated like other pain relief drugs but said he could not favor legalizing its recreational use. “Under medical marijuana, I believe it should be like any other drug,” Adams said Friday in Indianapolis. “We need to let the FDA vet it, […]

by

Dravet syndrome is a serious form of childhood epilepsy that first shows up in babies at six to nine months old, resulting in cognitive impairments, autistic-like behaviors, and premature death.  About 15 percent of children with Dravet syndrome die before they reach the age of 13, according to William Catterall, a lead researcher, professor, and […]

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

­­ NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended September 30, 2017, and provided an overview of recent operational highlights. “We are very excited to see clinical evidence of our theory and the therapeutic […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, […]

by

Results of a Phase 1 clinical trial in healthy volunteers show that PTL101, an oral cannabidiol compound, is a safe and effectively delivered potential treatment of spasticity in multiple sclerosis (MS) and for conditions like epilepsy, Harvest One Cannabis announced. These findings were published in the journal Clinical Pharmacology in Drug Development, in the study “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of […]

by

According to a report by Forbes, Brightfield Group, a cannabis market research firm indicates that the international market for cannabis is projected to hit $31.4 billion by 2021. Bethany Gomez, Director of Research for Brightfield Group, explained that the U.S. market is so much larger than the rest of the international markets combined. Currently, the […]

by

The FDA has recently issued warning letters to four companies concerning the marketing of products containing cannabidiol, alleging that claims made online concerning the health benefits of CBD violated the Federal Food, Drug and Cosmetic Act. The U.S. Food and Drug Administration (FDA) has recently issued warning letters to four companies concerning the marketing of […]

by